Pasquet J M, Bobe R, Gross B, Gratacap M P, Tomlinson M G, Payrastre B, Watson S P
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.
Biochem J. 1999 Aug 15;342 ( Pt 1)(Pt 1):171-7.
The collagen receptor glycoprotein VI (GPVI) induces platelet activation through a similar pathway to that used by immune receptors. In the present study we have investigated the role of phosphatidylinositol 3-kinase (PI 3-kinase) in GPVI signalling. Our results show that collagen-related peptide {CRP: GCP*(GPP*)(10)GCP*G; P*=hydroxyproline}, which is selective to GPVI, induces formation of phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P(3)] and phosphatidylinositol 3,4-bisphosphate [PI(3, 4)P(2)] in platelets. The increase in the two 3-phosphorylated lipids is inhibited completely by wortmannin and by LY294002, two structurally unrelated inhibitors of PI 3-kinase. The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. This is associated with inhibition of elevation of intracellular Ca(2+) (Ca(2+)) and aggregation. Wortmannin and LY294002 also partially inhibit elevation of Ca(2+) by CRP in murine megakaryocytes. Microinjection of the pleckstrin-homology PH domain of Bruton's tyrosine kinase, which binds selectively to PI(3,4, 5)P(3), but not the R28C (Arg(28)-->Cys) mutant which binds to PI(3, 4,5)P(3) with low affinity, also inhibits elevation of Ca(2+) in megakaryocytes, suggesting that it is this lipid species which mediates the action of the PI 3-kinase pathway. Studies in platelets show that the action of wortmannin and LY294002 is not mediated through an alteration in tyrosine phosphorylation of PLCgamma2. These results demonstrate that PI 3-kinase is required for full activation of PLCgamma2 by GPVI in platelets and megakaryocytes.
胶原蛋白受体糖蛋白VI(GPVI)通过与免疫受体相似的途径诱导血小板活化。在本研究中,我们研究了磷脂酰肌醇3激酶(PI 3激酶)在GPVI信号传导中的作用。我们的结果表明,对GPVI具有选择性的胶原蛋白相关肽{CRP:GCP*(GPP*)(10)GCP*G;P* = 羟脯氨酸}可诱导血小板中磷脂酰肌醇3,4,5-三磷酸[PI(3,4,5)P3]和磷脂酰肌醇3,4-二磷酸[PI(3,4)P2]的形成。这两种3-磷酸化脂质的增加被渥曼青霉素和LY294002完全抑制,这两种是结构不相关的PI 3激酶抑制剂。在渥曼青霉素和LY294002存在的情况下,CRP诱导的肌醇磷酸和磷脂酸(PA)(磷脂酶C(PLC)活化的两个标志物)的形成被抑制50%至85%。这与细胞内Ca(2+)([Ca(2+)]i)升高和聚集的抑制有关。渥曼青霉素和LY294002也部分抑制CRP在小鼠巨核细胞中引起的Ca(2+)升高。微注射布鲁顿酪氨酸激酶的普列克底物蛋白同源(PH)结构域(其选择性结合PI(3,4,5)P3),而非低亲和力结合PI(3,4,5)P3的R28C(精氨酸(28)-->半胱氨酸)突变体,也抑制巨核细胞中[Ca(2+)]i的升高,表明正是这种脂质介导了PI 3激酶途径的作用。血小板研究表明,渥曼青霉素和LY294002的作用不是通过改变PLCγ2的酪氨酸磷酸化来介导的。这些结果表明,PI 3激酶是血小板和巨核细胞中GPVI完全激活PLCγ2所必需的。